Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection

Background: SARS-CoV-2 infection is associated with thrombotic and microvascular complications. The cause of coagulopathy in the disease is incompletely understood. Methods: A single-center cross-sectional study including 66 adult COVID-19 patients (40 moderate, 26 severe disease), and 9 controls, p...

Full description

Bibliographic Details
Main Authors: Ivo M.B. Francischetti, Kevin Toomer, Yifan Zhang, Jayesh Jani, Zishan Siddiqui, Daniel J. Brotman, Jody E. Hooper, Thomas S. Kickler
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:EClinicalMedicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021003497
id doaj-b17b1d0611c3414abfb5f9cf23033c62
record_format Article
spelling doaj-b17b1d0611c3414abfb5f9cf23033c622021-09-25T05:10:56ZengElsevierEClinicalMedicine2589-53702021-09-0139101069Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infectionIvo M.B. Francischetti0Kevin Toomer1Yifan Zhang2Jayesh Jani3Zishan Siddiqui4Daniel J. Brotman5Jody E. Hooper6Thomas S. Kickler7Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Corresponding author.Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesDepartment of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United StatesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesBackground: SARS-CoV-2 infection is associated with thrombotic and microvascular complications. The cause of coagulopathy in the disease is incompletely understood. Methods: A single-center cross-sectional study including 66 adult COVID-19 patients (40 moderate, 26 severe disease), and 9 controls, performed between 04/2020 and 10/2020. Markers of coagulation, endothelial cell function [angiopoietin-1,-2, P-selectin, von Willebrand Factor Antigen (WF:Ag), von Willebrand Factor Ristocetin Cofactor, ADAMTS13, thrombomodulin, soluble Endothelial cell Protein C Receptor (sEPCR), Tissue Factor Pathway Inhibitor], neutrophil activation (elastase, citrullinated histones) and fibrinolysis (tissue-type plasminogen activator, plasminogen activator inhibitor-1) were evaluated using ELISA. Tissue Factor (TF) was estimated by antithrombin-FVIIa complex (AT/FVIIa) and microparticles-TF (MP-TF). We correlated each marker and determined its association with severity. Expression of pulmonary TF, thrombomodulin and EPCR was determined by immunohistochemistry in 9 autopsies. Findings: Comorbidities were frequent in both groups, with older age associated with severe disease. All patients were on prophylactic anticoagulants. Three patients (4.5%) developed pulmonary embolism. Mortality was 7.5%. Patients presented with mild alterations in the coagulogram (compensated state). Biomarkers of endothelial cell, neutrophil activation and fibrinolysis were elevated in severe vs moderate disease; AT/FVIIa and MP-TF levels were higher in severe patients. Logistic regression revealed an association of D-dimers, angiopoietin-1, vWF:Ag, thrombomodulin, white blood cells, absolute neutrophil count (ANC) and hemoglobin levels with severity, with ANC and vWF:Ag identified as independent factors. Notably, postmortem specimens demonstrated epithelial expression of TF in the lung of fatal COVID-19 cases with loss of thrombomodulin staining, implying in a shift towards a procoagulant state. Interpretation: Coagulation dysregulation has multifactorial etiology in SARS-Cov-2 infection. Upregulation of pulmonary TF with loss of thrombomodulin emerge as a potential link to immunothrombosis, and therapeutic targets in the disease. Funding: John Hopkins University School of Medicine.http://www.sciencedirect.com/science/article/pii/S2589537021003497ThrombosisHemostasisCoagulationIxolaris
collection DOAJ
language English
format Article
sources DOAJ
author Ivo M.B. Francischetti
Kevin Toomer
Yifan Zhang
Jayesh Jani
Zishan Siddiqui
Daniel J. Brotman
Jody E. Hooper
Thomas S. Kickler
spellingShingle Ivo M.B. Francischetti
Kevin Toomer
Yifan Zhang
Jayesh Jani
Zishan Siddiqui
Daniel J. Brotman
Jody E. Hooper
Thomas S. Kickler
Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection
EClinicalMedicine
Thrombosis
Hemostasis
Coagulation
Ixolaris
author_facet Ivo M.B. Francischetti
Kevin Toomer
Yifan Zhang
Jayesh Jani
Zishan Siddiqui
Daniel J. Brotman
Jody E. Hooper
Thomas S. Kickler
author_sort Ivo M.B. Francischetti
title Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection
title_short Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection
title_full Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection
title_fullStr Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection
title_full_unstemmed Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection
title_sort upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in sars-cov-2 infection
publisher Elsevier
series EClinicalMedicine
issn 2589-5370
publishDate 2021-09-01
description Background: SARS-CoV-2 infection is associated with thrombotic and microvascular complications. The cause of coagulopathy in the disease is incompletely understood. Methods: A single-center cross-sectional study including 66 adult COVID-19 patients (40 moderate, 26 severe disease), and 9 controls, performed between 04/2020 and 10/2020. Markers of coagulation, endothelial cell function [angiopoietin-1,-2, P-selectin, von Willebrand Factor Antigen (WF:Ag), von Willebrand Factor Ristocetin Cofactor, ADAMTS13, thrombomodulin, soluble Endothelial cell Protein C Receptor (sEPCR), Tissue Factor Pathway Inhibitor], neutrophil activation (elastase, citrullinated histones) and fibrinolysis (tissue-type plasminogen activator, plasminogen activator inhibitor-1) were evaluated using ELISA. Tissue Factor (TF) was estimated by antithrombin-FVIIa complex (AT/FVIIa) and microparticles-TF (MP-TF). We correlated each marker and determined its association with severity. Expression of pulmonary TF, thrombomodulin and EPCR was determined by immunohistochemistry in 9 autopsies. Findings: Comorbidities were frequent in both groups, with older age associated with severe disease. All patients were on prophylactic anticoagulants. Three patients (4.5%) developed pulmonary embolism. Mortality was 7.5%. Patients presented with mild alterations in the coagulogram (compensated state). Biomarkers of endothelial cell, neutrophil activation and fibrinolysis were elevated in severe vs moderate disease; AT/FVIIa and MP-TF levels were higher in severe patients. Logistic regression revealed an association of D-dimers, angiopoietin-1, vWF:Ag, thrombomodulin, white blood cells, absolute neutrophil count (ANC) and hemoglobin levels with severity, with ANC and vWF:Ag identified as independent factors. Notably, postmortem specimens demonstrated epithelial expression of TF in the lung of fatal COVID-19 cases with loss of thrombomodulin staining, implying in a shift towards a procoagulant state. Interpretation: Coagulation dysregulation has multifactorial etiology in SARS-Cov-2 infection. Upregulation of pulmonary TF with loss of thrombomodulin emerge as a potential link to immunothrombosis, and therapeutic targets in the disease. Funding: John Hopkins University School of Medicine.
topic Thrombosis
Hemostasis
Coagulation
Ixolaris
url http://www.sciencedirect.com/science/article/pii/S2589537021003497
work_keys_str_mv AT ivombfrancischetti upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection
AT kevintoomer upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection
AT yifanzhang upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection
AT jayeshjani upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection
AT zishansiddiqui upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection
AT danieljbrotman upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection
AT jodyehooper upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection
AT thomasskickler upregulationofpulmonarytissuefactorlossofthrombomodulinandimmunothrombosisinsarscov2infection
_version_ 1717368913243668480